NTLA vs VRTX

Intellia Therapeutics continues to demonstrate strong execution in its pioneering gene-editing pipeline. The positive Phase 3 data for lonvo-z in HAE and the initiation of its rolling BLA submission, targeting a 1H 2027 launch, are transformative. The FDA's lifting of clinical holds on nex-z trials further de-risks its broader platform. While the company remains unprofitable, its Q1 2026 earnings ...

Vertex Pharmaceuticals maintains its strong market position in Cystic Fibrosis and continues to advance a robust pipeline in high-growth areas like gene editing (Casgevy), non-opioid pain (VX-548), and Type 1 Diabetes. Recent FDA approval for expanded ALYFTREK use and solid Q4 2025 financials (revenue beat, strong EPS growth) underscore its operational strength and profitability. However, for a co...